Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

This study is testing a combination of two drugs — sacituzumab govitecan (a targeted antibody-drug conjugate) and bevacizumab (which cuts off blood supply to tumors) — for people with non-small cell lung cancer (NSCLC) that has spread to the brain. **You may be eligible if...** - You are 18 or older - You have been diagnosed with non-squamous NSCLC that has spread to the brain - You have at least one untreated brain metastasis of at least 5mm in size - Your cancer has already progressed on standard treatments (immunotherapy and/or chemotherapy, or targeted therapy) - Your general health and organ function are within acceptable ranges **You may NOT be eligible if...** - Cancer has spread to the lining of the brain (leptomeningeal disease) - You have previously been treated with a TROP2-targeting drug or an anti-angiogenic drug (bevacizumab or similar) - You have significant heart problems, active infections, or severe lung disease - You have active hepatitis B or C, or HIV with detectable viral load - You are pregnant or breastfeeding - You have had a prior bone marrow or organ transplant Talk to your doctor to see if this trial is right for you.